Expertise in
8
conditions

Dr. Kimmie Ng

Hematology Oncology | Oncology
Brigham and Women’s Hospital
Dana-Farber Brigham Cancer Center In Clinical Affiliation With South Shore Health
101 Columbian Street, South, 
South Weymouth, MA 
Expertise in
8
conditions
Brigham and Women’s Hospital
Dana-Farber Brigham Cancer Center In Clinical Affiliation With South Shore Health
101 Columbian Street, South, 
South Weymouth, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kimmie Ng is a Hematologist Oncology specialist and an Oncologist in South Weymouth, Massachusetts. Dr. Ng is highly rated in 8 conditions, according to our data. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, Pancreaticoduodenectomy, and Pancreatectomy.

Her clinical research consists of co-authoring 230 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Pennsylvania School Of Medicine, 2001
Residency
University of California, San Francisco School of Medicine, 2004
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in MA
Board Certifications
Internal Medicine
Medical Oncology
Fellowships
Dana-Farber/Partners CancerCare
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

Dana-Farber Brigham Cancer Center in clinical affiliation with South Shore Health
101 Columbian Street, South, South Weymouth, MA 02190
Call: 617-632-4150
Other Locations
Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street, Chestnut Hill, MA 02459
Call: 617-632-4150
Dana-Farber Cancer Institute, Center for Gastrointestinal Oncology
450 Brookline Avenue, Boston, MA 02115
Call: 617-632-4150

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
Enrollment Status: Terminated
Publish Date: August 29, 2025
Intervention Type: Other
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Dietary supplement, Drug
Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan
Study Phase: Phase 3
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Combination of MEK Inhibitor Binimetinib and CDK4/6 Inhibitor Palbociclib in KRAS and NRAS Mutant Metastatic Colorectal Cancers
Enrollment Status: Completed
Publish Date: August 22, 2024
Intervention Type: Drug
Study Drugs: Binimetinib, Palbociclib, Trifluridine+Tipiracil Hydrochloride
Study Phase: Phase 2
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Panitumumab, Regorafenib, Trifluridine, Tipiracil
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC
Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC
Enrollment Status: Completed
Publish Date: June 26, 2023
Intervention Type: Drug
Study Drugs: RMC-4630, Cobimetinib, Osimertinib
Study Phase: Phase 1/Phase 2
Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer
Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Patients With Previously Untreated Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 26, 2022
Intervention Type: Drug, Dietary supplement
Study Phase: Phase 2
BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer
BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: January 31, 2022
Intervention Type: Other, Drug, Biological
Study Phase: Phase 2
View 8 Less Clinical Trials

230 Total Publications

A Review of Early-Onset Gastrointestinal Cancers-Reply.
A Review of Early-Onset Gastrointestinal Cancers-Reply.
Journal: JAMA
Published: November 19, 2025
View All 230 Publications
Similar Doctors
Expertise in
22
conditions
Dr. David A. Reardon
Hematology Oncology | Hematology | Oncology
Expertise in
22
conditions
Dr. David A. Reardon
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Center For Neuro-Oncology

450 Brookline Avenue, 
Boston, MA 
 (0.1 miles away)
617-632-2166
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Reardon is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Reardon is highly rated in 22 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Tissue Biopsy.

Expertise in
20
conditions
Dr. Matthew S. Davids
Hematology Oncology | Oncology
Expertise in
20
conditions
Dr. Matthew S. Davids
Hematology Oncology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Davids is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Davids is highly rated in 20 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Davids is currently accepting new patients.

Expertise in
35
conditions
Dr. Edwin Choy
Hematology Oncology | Oncology
Expertise in
35
conditions
Dr. Edwin Choy
Hematology Oncology | Oncology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (2.7 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Edwin Choy is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Choy is highly rated in 35 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Osteosarcoma, and Synovial Sarcoma. Dr. Choy is currently accepting new patients.

VIEW MORE Hematologist Oncologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ng's expertise for a condition
ConditionClose
  • Elite
  • Colorectal Cancer
    Dr. Ng is
    Elite
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Distinguished
  • Familial Colorectal Cancer
    Dr. Ng is
    Distinguished
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Lynch Syndrome
    Dr. Ng is
    Distinguished
    . Learn about Lynch Syndrome.
    See more Lynch Syndrome experts
  • Advanced
  • Appendix Cancer
    Dr. Ng is
    Advanced
    . Learn about Appendix Cancer.
    See more Appendix Cancer experts
  • Gallbladder Adenocarcinoma
    Dr. Ng is
    Advanced
    . Learn about Gallbladder Adenocarcinoma.
    See more Gallbladder Adenocarcinoma experts
  • Gallbladder Cancer
    Dr. Ng is
    Advanced
    . Learn about Gallbladder Cancer.
    See more Gallbladder Cancer experts
  • Pancreatic Cancer
    Dr. Ng is
    Advanced
    . Learn about Pancreatic Cancer.
    See more Pancreatic Cancer experts
  • Stomach Cancer
    Dr. Ng is
    Advanced
    . Learn about Stomach Cancer.
    See more Stomach Cancer experts
  • Experienced
  • Anal Cancer
    Dr. Ng is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Breast Cancer
    Dr. Ng is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Ng is
    Experienced
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Esophageal Cancer
    Dr. Ng is
    Experienced
    . Learn about Esophageal Cancer.
    See more Esophageal Cancer experts
  • Familial Pancreatic Cancer
    Dr. Ng is
    Experienced
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Fibrolamellar Carcinoma
    Dr. Ng is
    Experienced
    . Learn about Fibrolamellar Carcinoma.
    See more Fibrolamellar Carcinoma experts
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
  1. Homepage
  2. Hematologist Oncologists South Weymouth, MA
  3. Dr. Kimmie Ng
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.